Results 21 to 30 of about 1,005 (173)

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis [PDF]

Neuropsychopharmacology Reports
Aim Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.
Yasufumi Nishii, Kenji Sakuma, Shun Hamanaka, Nakao Iwata, Taro Kishi   +4 more
doaj   +2 more sources

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review [PDF]

Brain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor‐e‐Ainaa, Hania Imran, James Hanna, Said Hamid Sadat   +12 more
wiley   +2 more sources

Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]

BMC Neurology
Background As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan, Jiwei Li, Yixin Yu, Shenghan Qiu, Bing Wang, Jiyou Tang   +5 more
doaj   +2 more sources

Histamine H3 receptor inverse agonists/antagonists influence intra-regional cortical activity and inter-regional synchronization during resting state: an exploratory cortex-wide imaging study in mice [PDF]

Molecular Brain
The histaminergic system plays a key role in modulating learning and memory, wakefulness, and energy balance. Histamine H3 receptors constitutively inhibit the synthesis and release of histamine and other neurotransmitters. Therefore, H3 receptor inverse
Sentaro Kaita, Yoshikazu Morishita, Kenta Kobayashi, Hiroshi Nomura   +3 more
doaj   +2 more sources

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]

Frontiers in Pharmacology
ObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou, Jia Chen, Bangtian Xu, Li Chen, Li Chen, Li Chen   +5 more
doaj   +2 more sources

Narcolepsy: a machine learning bibliometric analysis (1996–2024) [PDF]

Frontiers in Neurology
BackgroundNarcolepsy is a rare neurological cause of chronic sleepiness. This study aimed to better understand global narcolepsy through bibliometric analysis.MethodsArticles and reviews on narcolepsy were sourced from the Web of Science Core Collection.
Minheng Zhang, Xiaodong Hu, Haiyan Wu, Haixia Fan   +3 more
doaj   +2 more sources

The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice [PDF]

Scientific Reports
Autism spectrum disorder (ASD) is a prevalent neurodevelopmental condition characterized by repetitive behaviors, impaired sociability, and persistent neuroinflammation.
Malak Hajar, Petrilla Jayaprakash, Holger Stark, Bassem Sadek   +3 more
doaj   +2 more sources

Pentylenetetrazol-induced seizures and brain neuroinflammation markers under conditions of pitolisant and pioglitazone use

Journal of Education, Health and Sport
The purpose of the study was to investigate the dynamics of seizure activity and markers of neuroinflammation in kindled rats under conditions of individual and combined use of pitolisant and pioglitazone.
O. Yehorenko, M. Pervak
doaj   +3 more sources

Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP A Randomized Trial [PDF]

, 2021
BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION:
Pepin, Jean-Louis, Fietze, Ingo, Dauvilliers, Yves, Dokic, Dejan, Levy, Patrick, Verbraecken, Johan, Partinen, Markku, Lecomte, Jeanne-Marie, Tamisier, Renaud, Lecomte, Isabelle, Georgiev, Ognian, Belev, Georgi, Buyse, Bertien, Tiholov, Rumen, Schwartz, Jean-Charles, Attali, Valerie   +15 more
core   +3 more sources

Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease

International Journal of Molecular Sciences
Alzheimer’s disease (AD) is a complex and multifactorial neurodegenerative disorder characterized by cognitive decline, memory loss, behavioral changes, and other neurological symptoms. Considering the urgent need for new AD therapeutics, in the present study we designed, synthesized, and evaluated multitarget compounds structurally inspired by ...
Silvia Pérez-Silanes, Eva Martisova, Esther Moreno, Maite Solas, Daniel Plano, Carmen Sanmartin, María Javier Ramírez   +6 more
openaire   +4 more sources